Subsequent Events

6 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 15 – Subsequent Events

On January 16, 2024, the Company cancelled 1,250,000 shares of Series C Preferred Stock and 15,000,000 shares of common stock for no consideration.

On February 6, 2024, the Company entered into an amendment to the Benza Settlement Agreement (see Note 12). Within two days of the signing of this Amendment, the Company shall make total payments in the amount of $20,000 and a $10,000 payment made on or before April 5, 2024, to “GRQ. This $20,000 payment shall be credited to the Second Nevada Settlement Payment for the Benza Pharma LLC note as that term is defined in the Settlement Agreement. All outstanding principal and accrued interest shall be due on April 15, 2024 (the “Extended Due Date”).

The Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued and determined that there are no additional material events that are required to be disclosed.